"Fage" Counter attack: MediaTek's share of mobile phone chips peaked in the third quarter
"Fage" Counter attack: MediaTek's share of mobile phone chips peaked in the third quarter

On December 25, it was reported that, according to the statistical report published by CounterPoint, a foreign market research organization, among the mobile phones shipped worldwide in the third quarter of this year, the models equipped with MediaTek's SoC platform accounted for 31% of the market share, surpassing Qualcomm's 29% share and taking the first place in the market.

In the same period of last year, MediaTek still lagged behind Qualcomm by 5% in market share. After the efforts of this year, "Fage" can be said to have successfully achieved a counter attack. It can also be seen from the new machines released by various manufacturers this year that the sense of existence of the MediaTek platform is getting stronger and stronger.

Huawei HiSilicon, Samsung and Apple, three mobile phone manufacturers with the ability to develop their own chips, each accounted for 12% of the market share, while the other domestic chip manufacturer, Unisplendor, also accounted for 4% of the market share.

CounterPoint said that MediaTek's rise to the top was mainly due to the good performance of low-cost models equipped with its chips in the Chinese mainland and Indian markets. At the same time, although MediaTek has been developing 5G chips for a year, Qualcomm still has the largest share of 5G mobile phone chips.

Cai Lixing, CEO of MediaTek, said earlier that a new generation of 5G flagship chips would be launched as soon as the first quarter of 2021 before the Lunar New Year.



Follow our Weibo @ Love Computer

Follow our WeChat official account: playphone

Of course, we also pay attention to our Bilibili account: love computer

Share:
Harness the wind
edit
Slightly understand
Share Weibo Share WeChat
 Aigoji WeChat

Aigoji WeChat

 WeChat

WeChat

Recommended products

Sorry, the product you are looking for is not available in the product library

on trial